冷冻消融联合索拉非尼和IL-2治疗晚期转移性肾癌疗效观察  

Clinical observation of cryoablation combined with sorafenib and interleukin-2 in treatment of advanced metastatic renal cell carcinoma

作　　者：程海峰[1] 赵振民 杨庆民 平玉杰[1] 丁瑞[1] 文红壮[1] 李博科 王磊[1] 

机构地区：[1]河北省邯郸市中心医院泌尿外1科,056001 [2]河北省邯郸市第七医院外科 [3]河北省曲周县医院外科

出　　处：《河北医药》2018年第4期581-583,586,共4页Hebei Medical Journal

摘　　要：目的观察冷冻消融联合索拉非尼和IL-2治疗晚期转移性肾癌的临床疗效。方法选取2013年10月至2016年10月收治的晚期转移性肾癌患者90例,随机分为对照组和观察组,每组45例。对照组给予口服索拉非尼和静脉滴注IL-2治疗。治疗组先行局麻下冷冻消融治疗,2周后给予索拉菲尼和IL-2治疗。疗程均为4周。比较2组临床疗效、生活质量改善情况、不良反应、无进展生存时间、总生存时间。结果对照组有效率、临床获益率分别为53.33%和82.22%,观察组有效率、临床获益率分别为77.78%、95.56%,与对照组比较,观察组有效率和临床获益率显著提高,差异有统计学意义(P<0.05)。对照组和观察组生活质量改善率分别为51.11%、80.00%,与对照组比较,观察组生活质量改善率显著提高,差异有统计学意义(P<0.05)。对照组和观察组不良反应发生率分别为15.56%、4.44%,与对照组比较,观察组不良反应发生率显著降低,差异有统计学意义(P<0.05);且观察组无进展生存时间、总生存时间较对照组显著延长,差异有统计学意义(P<0.05)。结论冷冻消融联合索拉非尼和IL-2治疗晚期转移性肾癌临床疗效显著,能够明显改善患者生活质量和生存时间,且无明显不良反应,值得临床推广应用。Objective To observe the therapeutic effects of cryoablation combined with sorafenib and interleukin-2 on advanced metastatic renal cell carcinoma. Methods A total of 90 patients with advanced metastatic renal cell carcinoma who were admitted and treated in our hospital from October 2013 to October 2016 were enrolled in the study. These patients were randomly divided into observation group（ n = 45） and control group（ n = 45）. The patients in control group were treated by oral sorafenib tosylate tablets and intravenous drip with recombinant human interleukin-2,however,the patients in observation group were treated firstly by cryoablation under local anesthesia,after 2-week treatment,these patients were treated by oral sorafenib tosylate tablets and intravenous drip with recombinant human interleukin-2,with a treatment course of 4 weeks for both groups. The clinical curative effects, improvement of life quality, adverse reactions, overall survival time and progress-free survival time were observed and compared between two groups. Results After treatment,the total effective rate and clinical benefit rate in control group were 53. 33% and 82. 22%,respectively,which in observation group were 77. 78%and 95. 56%,respectively,there were significant differences between two groups（ P〈0. 05）. The improvement rate of life quality in observation group was 80. 00%,which was significantly higher than that（ 51. 11%） in control group（ P〈0. 05）.However the incidence rate of adverse reactions in observation group was 4. 44%,which was significantly lower than that（ 15. 56%） in control group（ P〈0. 05）. In addition the overall survival time and progress-free survival time in observation group were significantly longer than those in control group（ P〈0. 05）. Conclusion The cryoablation combined with sorafenib and interleukin-2 has obvious therapeutic effects on advanced metastatic renal cell carcinoma,which can significantly improve the life quality and survival time of patients,without obvious ad

关 键 词：冷冻消融 索拉非尼 注射用重组人白细胞介素-2 晚期转移性肾癌 疗效 

分 类 号：R737.11[医药卫生—肿瘤]